GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback